×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Head & Neck Cancer
Katie Kosko
The investigational agent tipifarnib shows promise in patients with head and neck cancer who have a certain gene mutation.
Collins Branche
Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Jason Mendelsohn, a stage 4 HPV-related throat cancer survivor who created a web site geared to raising awareness about HPV-related cancers.
Jessica Skarzynski and Katie Kosko
Poison’s Rikki Rockett discusses the immunotherapy clinical trial that led him into remission.
Kristie L. Kahl
In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with a caregiver about support for others taking care of a loved one with cancer through a letter she wrote to her younger self.
Kristie L. Kahl
The Food and Drug Administration has approved Keytruda for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus in certain patients.
Alexandra Guadagno
From Beth Chapman’s untimely passing to cancer fundraising via esports, here’s what is making headlines in the cancer space this week.
Kristie L. Kahl
The Food and Drug Administration approved Keytruda monotherapy and in combination with chemotherapy for the front-line treatments of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.
Alexandra Guadagno
From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.
Heather Stringer
Patients with head and neck cancer may soon have more effective, less toxic choices as immunotherapy moves into first-line treatment and novel targeted drugs are explored.